PUBLISHER: Renub Research | PRODUCT CODE: 1498417
PUBLISHER: Renub Research | PRODUCT CODE: 1498417
Global Human Microbiome Market will grow US$ 3.05 Billion by 2032 from US$ 0.72 Billion in 2023, with a CAGR of 17.48% during 2023-2032.
The human microbiome is a collection of microorganisms found on and within the human body. It contains various organisms, including bacteriophages, bacteria, fungi, viruses, and protozoa. The microbiota might weigh up to five pounds and help control our immune system, digest our food, defend against other disease-causing bacteria, and generate vitamins such as B and Vitamin K. The human microbiome is a market with immense potential, including bacteria, archaea, viruses, and eukaryotes inside and outside our bodies. The demand for prebiotics and probiotics is expected to grow significantly due to increased awareness about their role in preventive health measures. Factors driving this growth include the rising geriatric population, the growing prevalence of lifestyle diseases, and government funding for initiatives like the 'Human Microbiome Project' and 'the Earth Microbiome.' These initiatives provide opportunities for market players to research and develop new products, driving market growth during the forecast period.
The human microbiome is a significant area of study and has the potential to revolutionize healthcare. It is related to the rise of lifestyle-related diseases and the aging population, and it directly affects conditions such as diabetes. The International Diabetes Federation 2021 statistics show that there are 52.7 million people aged 20-79 years in Europe with diabetes, which is expected to reach 69 million by 2045. The diversity of gut microbes, particularly the presence of butyrate-producing bacteria, has a significant impact on insulin resistance and the risk of type 2 diabetes, demonstrating the influence of the human microbiome on health. This rise in lifestyle-related illnesses, such as diabetes, will fuel market growth during the upcoming years.
Persephone Biosciences Inc. is developing immune-boosting microbiome therapeutics to prevent and treat COVID-19. They also work on a stool-based diagnostic test to identify patients at risk for severe complications. The pandemic has increased awareness of microbiota therapies and diagnosis, leading to a growing market for these solutions.
Seres Therapeutics Inc. and Nestle Health Science collaborated to jointly commercialize an investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection in Canada and the United States. This collaboration aims to boost market segment growth and strengthen the position of the market players, potentially leading to a new treatment modality.
North American Human Microbiome Market
The United States is the largest market in North America for the human microbiome, followed by Canada. The American Cancer Society predicts that there will be approximately 1,918,030 new cancer diagnoses in the United States in 2022. According to Globocan 2020 data, there are 274,364 new cancer instances, which is expected to reach 400,564 by 2040. The rising incidence of cancer is expected to drive market expansion due to the role of gut microbiota in regulating tumor therapy and improving patients' response to immunotherapy while reducing the adverse effects of chemotherapeutic drugs. This market expansion is further supported by an increasing number of research studies and the backing of regulatory bodies for investigation. 4D Pharma plc received FDA approval in February 2022 for two Live Biotherapeutics, MRx0005 and MRx0029, as investigational new drugs (IND) to treat Parkinson's disease. These approvals are expected to impact the market's development positively.
Human Microbiome Company Analysis
Prominent players in the Global Human Microbiome Market include DuPont, Evelo Biosciences Inc., Finch Therapeutics Group Inc., Ginkgo Bioworks, Seres Therapeutics, AOBiome, Astarte Medical, Axial Biotherapeutics, Inc. and Osel Inc.
Human Microbiome Company News
Sept 2022: The FDA has completed the BLA application process for Seres Therapeutics Inc.'s SER-109 drug, a groundbreaking approach to treating recurrent C. difficile infection. This innovative treatment aims to elevate the current standard of care for rCDI.
Sept 2022: The FDA's Vaccines and Related Biological Products Advisory Committee approved Ferring Pharmaceuticals' RBX2660 investigational microbiota-based live biotherapeutic trial to reduce C. difficile infection (CDI) recurrence after antibiotic therapy.
September 2022: Seres Therapeutics Inc. completed the submission process for its BLA application to the FDA for SER-109 to prevent recurrent C. difficile infection (rCDI). It is an entirely new treatment modality that promises to improve the current standard of medical care for rCDI.
September 2022: Ferring Pharmaceuticals received a positive vote for RBX2660 by the FDA's Vaccines and Related Biological Products Advisory Committee for its investigational microbiota-based live biotherapeutic study, which has the potential to reduce the recurrence of C. difficile infection (CDI) after antibiotic treatment.
Application - Global Human Microbiome Market breakup into 2 Viewpoints
Disease - Global Human Microbiome Market breakup into 7 Viewpoints
Product - Global Human Microbiome Market breakup into 4 Viewpoints
Geography - Global Human Microbiome breakup of 25 Countries
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
All the Key players have been covered from 4 Viewpoints:
Companies List